Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Lyerly

Showing results (11-20 of 218) with videos related to

Pageof 22
Sort By:
North Carolina Medical Journal|September 20, 2018
The Health Impacts of Environmental Policy: The North Carolina Clean Smokestacks ActJulia Kravchenko, H Kim Lyerly, William Ross
Plos One|July 9, 2021
Exposure to low-dose ambient fine particulate matter PM2.5 and Alzheimer's disease, non-Alzheimer's dementia, and Parkinson's disease in North CarolinaSung Han Rhew, Julia Kravchenko, H Kim Lyerly
Expert Opinion on Biological Therapy|April 17, 2002
Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenesTimothy M Clay, Michael Morse, H Kim Lyerly
Current Treatment Options in Oncology|June 18, 2016
Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal CancerDionisia Quiroga, H Kim Lyerly, Michael A Morse
Journal of Public Health Management and Practice : JPHMP|July 31, 2013
Bridging the information gap between health and the environment in North CarolinaGregory D Kearney, Mina Shehee, H Kim Lyerly
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2018
Right Time and Place for IL12: Targeted Delivery Stimulates Immune TherapyH Kim Lyerly, Takuya Osada, Zachary C Hartman
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
CEA loaded dendritic cell vaccinesMichael A Morse, Timothy M Clay, H Kim Lyerly
Journal of Cellular Biochemistry|June 13, 2006
Gene therapy for lung cancerEric M Toloza, Michael A Morse, H Kim Lyerly
Expert Opinion on Biological Therapy|March 14, 2002
Current status of adoptive immunotherapy of malignanciesMichael A Morse, Timothy M Clay, H Kim Lyerly
Oncotarget|January 18, 2021
Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitorsErika J Crosby, H Kim Lyerly, Zachary C Hartman
Pageof 22

Showing results (11-20 of 218) with videos related to

Sort By:
Pageof 22
North Carolina Medical Journal|September 20, 2018
The Health Impacts of Environmental Policy: The North Carolina Clean Smokestacks ActJulia Kravchenko, H Kim Lyerly, William Ross
Plos One|July 9, 2021
Exposure to low-dose ambient fine particulate matter PM2.5 and Alzheimer's disease, non-Alzheimer's dementia, and Parkinson's disease in North CarolinaSung Han Rhew, Julia Kravchenko, H Kim Lyerly
Expert Opinion on Biological Therapy|April 17, 2002
Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenesTimothy M Clay, Michael Morse, H Kim Lyerly
Current Treatment Options in Oncology|June 18, 2016
Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal CancerDionisia Quiroga, H Kim Lyerly, Michael A Morse
Journal of Public Health Management and Practice : JPHMP|July 31, 2013
Bridging the information gap between health and the environment in North CarolinaGregory D Kearney, Mina Shehee, H Kim Lyerly
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2018
Right Time and Place for IL12: Targeted Delivery Stimulates Immune TherapyH Kim Lyerly, Takuya Osada, Zachary C Hartman
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
CEA loaded dendritic cell vaccinesMichael A Morse, Timothy M Clay, H Kim Lyerly
Journal of Cellular Biochemistry|June 13, 2006
Gene therapy for lung cancerEric M Toloza, Michael A Morse, H Kim Lyerly
Expert Opinion on Biological Therapy|March 14, 2002
Current status of adoptive immunotherapy of malignanciesMichael A Morse, Timothy M Clay, H Kim Lyerly
Oncotarget|January 18, 2021
Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitorsErika J Crosby, H Kim Lyerly, Zachary C Hartman
Pageof 22